50 results about "Sulforaphane" patented technology

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention belongs to the technical field of health-care products, and particularly relates to a fermented composition beneficial to enhancing immunity and a preparation method thereof. The fermentation composition for improving immunity is prepared by taking yeast beta-glucan, an elderberry extract, glucoraphanin, sea cucumber peptide, inulin and a traditional Chinese medicine zymolyte as fermentation raw materials, firstly inoculating bacillus coagulans and staphylococcus xylosus for aerobic fermentation, and then inoculating bifidobacterium longum for anaerobic fermentation, the aerobic fermentation stage and the anaerobic fermentation stage have a synergistic effect, so that the fermentation speed can be increased, the fermentation time can be shortened, and richer nutrient substances can be provided, and therefore, the composition has an excellent effect of enhancing the immunity; the fermentation composition is applied to preparation of capsules helpful for enhancing immunity, is helpful for enhancing human immunity, and can solve the problem that active substances in existing health-care products are difficult to effectively absorb by human bodies, so that the effect of enhancing immunity is influenced.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and / or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.

The invention discloses application of sulforaphane, and belongs to the field of medicine. Experiments with mouse AML-12 cells find that when the mouse AML-12 cells are jointly treated with sulforaphane and alpha-amatoxin, the inhibition effect of alpha-amatoxin on the activity of the AML-12 cells can be effectively relieved, the ROS level in the cells can be reduced, cell oxidative stress injury can be relieved, mitochondrial membrane potential reduction can be inhibited, and the mouse AML-12 cells can be treated with raphane and alpha-amatoxin. The sulforaphane can be used for relieving alpha-amatoxin induced mouse AML-12 cell mitochondrial injury, so that the sulforaphane can become a novel medicine for relieving alpha-amatoxin poisoning. The new application of the sulforaphane is found for the first time, and a new substance is provided for preparing the medicine for relieving alpha-amatoxin poisoning.

To provide compositions for increasing the level of NAD(P)H:quinone oxidoreductase 1 (NQO-1), or increasing its gene expression.SOLUTION: Provided is a composition for increasing the level of NAD(P)H:quinone oxidoreductase 1 (NQO-1) or increasing its gene expression in a subject. The composition comprises a combination of sulforaphane and a glucan as active ingredients, which combine to produce a synergistic effect between the active ingredients. The glucan is provided as a Ganoderma lucidum extract or powder. The Ganoderma lucidum extract preferably contains about 1 to about 75 wt.% of one or more glucans. Furthermore, the one or more glucans are preferably β-glucan and / or 1,3-β-glucan and / or 1,6-β-glucan.SELECTED DRAWING: Figure 1

The present invention is characterized by being a novel sulforaphane derivative comprising a complex of sulforaphane (1-isothiocyanato-4-[methylsulfinyl]butane (SFN)) and cysteine persulfide (CysSnH, n=2, 3, 4, or 5) or glutathione persulfide (GSnH or GSnG, n=2, 3, 4, or 5).

The invention discloses a chitosan modified turmeric-broccoli exosome hybrid nasal spray and application thereof, and belongs to the technical field of biological medicine and drug delivery. The nasal spray is formed by dispersing double plant exosome-lipidosome hybrids in a carrier for nasal cavities. The preparation method comprises the following steps: fusing curcumin carried by a turmeric exosome and sulforaphane carried by a broccoli bud exosome with a pH response liposome membrane containing 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine, and modifying by chitosan to form a three-layer structure; the preparation method comprises the steps of exosome extraction, ultrasonic drug loading, liposome hybridization, chitosan coating and preparation blending. The nasal spray is high in entrapment efficiency and uniform in particle size, the chitosan enhances nasal adhesion, inflammation targeted drug release is achieved through pH response, the brain targeting efficiency and stability are excellent, and the adaptability to children is good. The curcumin and sulforaphane are used for targeted therapy of children autism spectrum disorder neuroinflammation, anti-inflammation and anti-oxidation are achieved through synergism of curcumin and sulforaphane, the curative effect is remarkable, and a new scheme is provided for treatment of related diseases.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

This invention discloses a composition for female ovarian maintenance and its preparation method, relating to the field of health care compositions, including the following steps: mixing pectin and sweetener, dissolving in water to obtain material A; then mixing the traditional Chinese medicine formula, material A, active ingredients, resistant dextrin, vitamins, flavoring agents, and edible flavorings in sequence; stirring after adjusting the volume with purified water, then filtering, filling, sterilizing, and packaging to obtain a composition for female ovarian maintenance; this invention improves the utilization rate of functional components through the immobilization of fructooligosaccharides and β-glucosidase and the enteric coating targeting of shellac; Poria cocos polysaccharide-sulforaphane-resveratrol covers immune, antioxidant, and metabolic regulation pathways, directly targeting the core mechanism of premature ovarian failure; in summary, through the optimization of the entire chain of delivery-conversion-absorption-metabolism, the efficacy is significantly improved under the premise of safety.

This invention relates to broccoli rich in sulforaphane and indole-3-methanol, its preparation method, and its applications, belonging to the field of food technology. To increase the content of sulforaphane and indole-3-methanol in broccoli, this invention provides a broccoli rich in sulforaphane and indole-3-methanol and its preparation method. This invention utilizes expression vectors or recombinant bacteria overexpressing the BoSULTR1;1 and BoSULTR1;2 genes to prepare transgenic broccoli plants. Nutrient content determination results of the above transgenic broccoli plants show that the BoSULTR1;1 and BoSULTR1;2 genes increase the content of sulforaphane and indole-3-methanol in broccoli by increasing the content of the precursor substances sulforaphane and brassinosteroides. This invention achieves the goal of simultaneously increasing the content of sulforaphane and indole-3-methanol in broccoli, significantly improving the nutritional value of broccoli, and can be applied to the production of foods beneficial to health.

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

The present invention relates to a nutritional targeting composition which comprises a component 1 providing glucoraphanin, a component 2 providing myrosinase and magnesium stearate and which efficiently releases sulforaphane to activate NRF2 targets. The present invention also relates to the use of the composition in the preparation of products for preventing or treating diseases or conditions which can be prevented or treated by using sulforaphane.

The application discloses application of sulforaphane in preparation of an antienterovirus drug and belongs to the technical field of medicines, wherein the sulforaphane can inhibit the expression of viral proteins, inhibit viral genome replication and inhibit the production of virus particles to achieve the purpose of resisting enteroviruses; specifically, the sulforaphane can inhibit the replication of enteroviruses by up-regulating the content of p53 proteins. In addition, the sulforaphane can also be used for reducing the cell morphological damage caused by enteroviruses.

The invention discloses a preparation method of SFN-loaded ZIF-8 composite hydrogel. The preparation method specifically comprises the following steps: step 1, preparing ZIF-8 nanoparticles; step 2, preparing ZIF-8 nano particles loaded with the SFN; and step 3, preparing the ZIF-8 composite hydrogel loaded with the SFN. SFN is adopted as a medicine, ZIF-8 nano-particles with osteogenesis promoting and antibacterial effects are adopted as a carrier, SFN-loaded ZIF-8 nano-drug-loaded particles are synthesized, the SFN-loaded ZIF-8 nano-particles are combined with the hydrogel, the local concentration of SFN at the periodontitis diseased region can be effectively improved, the bioavailability of SFN can be improved, the hydrogel has injectability, and the hydrogel can be used for preparing the medicine for treating periodontitis. The drug-loaded nanoparticles are sent to the deep part of a periodontal pocket, and only a minimally invasive wound is generated. The invention also discloses the SFN-loaded ZIF-8 composite hydrogel and an application of the SFN-loaded ZIF-8 composite hydrogel in preparation of a medicine for treating periodontitis.

The invention discloses a method for increasing the content of sulforaphane in broccoli through magnetic field assisted blanching, and belongs to the technical field of food processing. The method for improving the content of sulforaphane in broccoli through magnetic field assisted blanching comprises the following steps: (1) preparing raw materials; (2) magnetic field assisted blanching pretreatment; (3) cooling and structure keeping treatment; (4) carrying out enzymatic incubation based on a magnetic field-assisted blanching regulation state; and (5) obtaining the broccoli product with high sulforaphane content. Exogenous enzymes, chemical reagents or additives are not introduced in the process, and the activity of endogenous myrosinase and the catalytic hydrolysis path of the endogenous myrosinase are regulated by synchronously applying a physical regulation means in the blanching pretreatment process, so that the generation level of sulforaphane in a treated sample is improved. The method is suitable for a food processing system, has the advantages of mild process conditions, strong controllability, high safety and easiness in industrial amplification, and has a wide application prospect in the field of food processing.

The invention relates to the technical field of aquaculture feed additives, and discloses a sulforaphane-containing weever anti-stress powder additive as well as a preparation method and application thereof. The natural plant extract sulforaphane, the high-quality protein source, the compound vitamins and the mineral substances are scientifically proportioned, so that the survival rate and the meat quality of the perches under the adverse conditions of high temperature, low oxygen, transportation and the like can be remarkably improved. The feed additive adopts a low-temperature granulation process, can effectively maintain the stability of active ingredients, and ensures that the active ingredients do not lose efficacy in a long-term storage process.

The invention discloses an anti-inflammatory and anti-aging face cream and a preparation method thereof, and belongs to the technical field of cosmetics. The face cream disclosed by the invention is prepared from the following components in percentage by weight: 5.0 to 20.0 percent of broccoli fermentation filtrate, 0.05 to 0.2 percent of andrographolide encapsulated by nano-liposome, 0.5 to 5.0 percent of a skin barrier repairing agent and a matrix. Sulforaphane (greater than or equal to 400 mg / kg) in broccoli is enriched through a lactic acid bacteria fermentation technology, and the stability and the smell of the broccoli are improved; the problem that andrographolide is difficult to dissolve and easy to crystallize is solved through embedding of nano-liposome (the particle size is 40-80 nm, and the encapsulation efficiency is larger than or equal to 85%), and the transdermal property of andrographolide is improved. The two are combined to synergistically activate an Nrf2 antioxidant pathway and inhibit an NF-kappa B inflammation pathway, and the two pathways intervene in inflammatory aging. Human body tests show that after the face cream is used for 4 weeks, the depth of wrinkles can be remarkably reduced (28.6%), the level of skin inflammatory factors TNF-alpha can be reduced (50.4%), and the face cream is free of any irritating reaction, has an excellent anti-aging effect and extremely high safety and is particularly suitable for sensitive skin.

The present invention relates to a nutritional targeting composition which comprises a component 1 providing glucoraphanin, a component 2 providing myrosinase and magnesium stearate and which efficiently releases sulforaphane to activate NRF2 targets. The present invention also relates to the use of the composition in the preparation of products for preventing or treating diseases or conditions which can be prevented or treated by using sulforaphane.

The present disclosure discloses a Lactobacillus plantarum ZUST49 and a bacterial agent, and use thereof, and belongs to the technical field of microorganisms. An aspect of the present disclosure provides a Lactobacillus plantarum ZUST49 and a bacterial agent containing the Lactobacillus plantarum ZUST49, and another aspect provides use of the Lactobacillus plantarum ZUST49 and the bacterial agent containing the Lactobacillus plantarum ZUST49. The Lactobacillus plantarum ZUST49 of the present disclosure may convert glucoraphanin into sulforaphane, especially in a human or animal intestinal environment. After an enteric probiotic preparation prepared from the strain of the present disclosure is orally taken, the Lactobacillus plantarum ZUST49 may efficiently convert the glucoraphanin into the sulforaphane in an intestinal tract, which not only solves a problem that stability of the sulforaphane cannot be improved in the prior art, but also effectively exerts a probiotic effect.

The invention belongs to the technical field of biomedical engineering, and particularly relates to an induction system for improving somatic cell reprogramming efficiency and a reprogramming method. The induction system comprises a carrier for expressing Oct4, Sox2 and Klf4 transcription factors, and sulforaphane. According to the induction system, on the basis of a classical four-factor reprogramming system, a c-Myc factor with a tumorigenic risk is removed, only Oct4, Sox2 and Klf4 three-factor expression vectors are reserved, and a natural antioxidant sulforaphane with the concentration of 2 [mu] M is innovatively introduced, so that the tumorigenic hidden danger caused by c-Myc is fundamentally avoided, the safety pain point of a traditional four-factor system is solved, and the induction system has the advantages of being simple in structure and convenient to operate. And by adding the sulforaphane, the reprogramming efficiency of the MEFs to the pluripotent iPSCs is improved by 6 times, and the high efficiency of reprogramming is realized.

A sleep supplement formulation that improves a person's sleep includes Sulforaphane and at least one additional ingredient selected from the following: Evodia Fruit Extract, Vitamin C, Quercetin, Red Sage, Angelica Dahruica Root, Golden Seal, L-Tryptophan, L-Theanine, Melatonin, Vitamin B6, Magnesium, Zinc, Ashwagandha Leaf and Root Extract, Chamomile Flower Extract, Gamma Aminobutyric Acid (GABA), Glycine, Valerian Root, and Lemon Balm Extract. A method of mitigating the effects of caffeine on a person's sleep includes orally administering to the person the sleep supplement formulation.

The disclosure relates to the technical field of dietary nutritional supplements, in particular to a hirudin formula composition with anticoagulant and hypolipidemic effects and a preparation method thereof. Technical problem: the hirudin formula composition with anticoagulant and hypolipidemic effects and the preparation method thereof are intended to solve the technical problems that dietary nutritional supplements in the prior art cannot achieve anticoagulant and hypolipidemic effects. Technical solution: a hirudin formula composition with anticoagulant and hypolipidemic effects includes the following components by weight: 50 mg to 500 mg of hirudin polypeptide, 10 mg to 100 mg of red yeast rice, 10 mg to 100 mg of nattokinase, 10 mg to 100 mg of sulforaphane, 10 mg to 100 mg of agaricus blazei murill, 10 mg to 100 mg of quercetin, 10 mg to 300 mg of hirudin, and 50 mg to 300 mg of panax notoginseng extract.

A nutraceutical composition, consisting of Nicotinamide Riboside in a range of 100-2000 mg or Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The present invention relates to a nutrition targeting composition comprising a component 1 providing sulforaphane glucosinolate, a component 2 providing myrosinase and magnesium stearate for efficient release of sulforaphane activating the NRF2 target, and the use of said composition for the preparation of a product for the prevention or treatment of a disease or condition that can be prevented or treated with sulforaphane.

Compositions and methods for converting at least one glucosinolate to an isothiocyanate using Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and / or Pediococcus pentosaceus M2_H12, or active variants thereof, are provided. Conversion of glucosinolates, such as glucoraphanin, to isothiocyanates, such as sulforaphane, leads to the stimulation of the Nrf2 / Keap pathway and phase II enzymes, providing chemoprotective and anti-inflammatory effects. Accordingly, provided herein are compositions comprising Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and / or Pediococcus pentosaceus M2_H12, or active variants thereof, for administration to subjects for increasing isothiocyanate (e.g., sulforaphane) production, increasing the expression of genes regulated by the Nrf2 transcription factor, including phase II enzymes, decreasing inflammation, and treating or preventing an inflammatory disorder or a cancer. The composition can comprise at least one glucosinolate or a plant, plant part or an extract thereof comprising glucosinolate(s).